Introduction: Learning health care systems (LHS) hold the promise of improving medical care
| THE ETHICAL TENSION
The characteristics that make pragmatic RCTs of standard-of-care interventions so valuable, however, create an inevitable tension with existing ethical frameworks for overseeing clinical trials. Specifically, the vision of a low-cost, pragmatic, continuous program of RCTs mimicking ordinary health care delivery appears incompatible, or at least in tension, with the requirement to obtain written informed consent (often involving lengthy and detailed forms), leading some observers to comment that the requirement of informed consent is a "critical barrier" for comparative effectiveness RCTs. 4 To incorporate a lengthy informed consent process would be in tension with the ordinary workflow of a busy clinic (such a practice would not mimic "real world"
practice in which most interventions do not require detailed written consent) and would be so costly as to make a continuous integrated practice of RCTs not feasible.
How should this tension be resolved? A notable feature of comparative effectiveness research involving standard of care treatments is that every participant will receive a clinically accepted or at least commonly used intervention for his or her condition, as distinct from trials of novel or experimental interventions. 5 Thus, some commentators note that "… standard-of-care research does not expose participants to risk beyond the risk they might be exposed to outside the study." 6, 7 Indeed, some argue that within learning health systems, the traditional distinction between research and treatment is problematic and outmoded 8, 9 and that the regulations "no longer match current needs" 8 and others argue that some types of RCTs do not need informed consent. 10 One group has developed a framework of moral principles for evaluating the ethics of LHS activities.
11
They argue that, following others, 12 these principles yield the result that in some pragmatic comparative effectiveness trials, the randomized assignment of treatments need not be disclosed to patients, and thus, no express informed consent for research participation is ethically necessary.
10
Comparative effectiveness research of 2 or more interventions, even when they are "within the standard of care," has generated much ethical controversy, as exemplified in the • Modify the RCT and conduct with traditional IC; less pragmatic but 'pragmatic enough.' • Not conduct the RCT because modifying it to accommodate traditional IC will make it not worth doing scientifically or would require resources that are not available.
Some have advocated-if cultural changes in the future lead to an overall acceptance of the mission and practice of LHS by patients in a health system-that perhaps general notification and some form of broad permission regarding future well-vetted standard-of-care RCTs without express consent might be sufficient. 19 Finally, it is theoretically possible that a standard-of-care RCT may meet the ethical requirements for a complete waiver of research consent without any general notifications, although that seems rather unlikely.
Of course, it is always possible that a thorough ethical analysis of a proposed standard-of-care RCT may determine that no deviation from the traditional informed consent procedures is permissible. In such a case, there are only 2 options for the researcher in the LHS.
One, the RCT could be modified to accommodate a traditional informed consent process. Such a modified RCT may still be scientifically valuable and worth doing. However, it may turn out that to incorporate a full informed consent process for a given standardof-care RCT would be such that either the cost would be prohibitive or the required modification to the RCT would make the study scientifically not worthwhile.
These options fairly exhaust the list of potential outcomes for ethically resolving the tension between a standard-of-care RCT and traditional consent process (with one caveat-see section on impracticability below). We now move on to the key issues that must be addressed in determining which of the above options is most ethically appropriate for a given standard-of-care RCT.
| DETERMINING THE OPTIMAL ETHICAL OPTION
At least in the United States, there are regulatory provisions for reviewing when a deviation from traditional research informed consent is permissible. (For some options in Table 1 , the issue will be a waiver of documentation of consent as per 45CFR46.117 rather than any question of waiving or altering the informed consent process itself).
These provisions actually do raise the key ethical issues relevant for bypassing informed consent, and practically speaking, they are the conditions that must be met, so we focus on how they might apply to standard-of-care RCTs. 20 To waive or alter informed consent, the research procedures must meet the following criteria listed in Table 2 .
These criteria are more thoroughly discussed elsewhere. [20] [21] [22] [23] For the present purpose, I simply present the type of issues that need to be addressed in applying the criteria. The fourth criterion of debriefing is not discussed here as it is an after the fact issue, and the focus here is on prospective deviations from usual practice of informed consent.
The most important point about the application of these criteria is RCT. 26 
| Are not all standard of care RCTs minimal risk?
Although it may seem that if everyone in the standard-of-care RCT receives standard of care treatment, the incremental risk or burden attributable to the research is very low. But this will depend on a few issues. It can be shown formally that if one or both of the following conditions are met, then the average incremental risk attributable to research participation will be minimal: (1) if the ex ante risk estimate of the 2 standard-of-care interventions is similar; (2) if the allocation ratio of the 2 interventions is similar inside and outside the RCT. 21 A full explication of the above 2 conditions can be found elsewhere 21 but for present purposes, we note that not all standard-of-care
RCTs have 2 interventions with similar ex ante risk and benefit profiles.
It may be that there have been a series of small RCTs favoring one intervention over another, but the data are not definitive enough. 21, 27 For instance, the United Kingdom Dermatology Clinical Trials Network compared the effectiveness of antibiotic prophylaxis (vs no prophylaxis) for recurrent cellulitis. 28 Prior to the trial, 4 randomized controlled trials had suggested possible benefits of antibiotic prophylaxis, although none of the studies were seen to provide definitive results, either because the sample size was small (2 studies) or because the benefits observed were statistically marginal (2 studies). [29] [30] [31] [32] Professional guidelines at the time recommended prophylactic antibiotic therapy. 33, 34 Further, for a particular individual, it is possible that entering an RCT will change the treatment that they receive. 15 Suppose that the standard practice in Mr A's clinic is to use antibiotic prophylaxis for his recurrent cellulitis. But in the standard-of-care RCT, he would have a 50% chance of receiving no prophylaxis instead. It is of course true that it could turn out that no prophylaxis is better, same, or worse than prophylaxis. But it is also true that ex ante risk analysis suggests that for Mr A, the incremental research risk is not negligible.
The analysis of incremental research risks of standard-of-care
RCTs turns out to be quite complex. The point here is that a thorough An IRB may approve a consent procedure, which does not include, or which alters, some or all of the elements of informed consent set forth in this section, or waive the requirements to obtain informed consent provided the IRB finds and documents that: (1) The research involves no more than minimal risk to the subjects; (2) The waiver or alteration will not adversely affect the rights and welfare of the subjects; (3) The research could not practicably be carried out without the waiver or alteration; and (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.
and systematic, case by case analysis is required and that the mere fact of 2 standard-of-care treatments being compared does not imply that the RCT is minimal risk.
| Waiver or alteration does not adversely affect rights and welfare of participants
This condition states that the waiver or alteration does not disadvantage participants by depriving them of goods that they otherwise would be entitled to expect. For example, there may be regulations or laws aside from the research regulations that confer on the participants certain rights to information. Or they would have benefited from some arrangement that they would fully expect to receive but which would be threatened if the waiver or alteration were granted.
The most obvious way in which this condition would apply is in regard to their expectation that certain types of medical decisions are "preference sensitive"-that is, in some quantitative sense, the overall utility of the 2 treatments might be similar, but the nature of the treatments is such that personal preferences are important to consider. For example, in a study testing 2 surgical procedures for breast cancer, one procedure might be more invasive and disfiguring with greater adverse effects but may be thought by many surgeons to be more effective. 35 A specific patient may nonetheless prefer or value one treatment over another given the kinds of benefits and harms involved. In fact, patients do vary widely in their preferences in this domain. 36 It is not difficult to see that these are precisely the kinds of situations in which the patients' preferences are especially important-thus, some standard-of-care RCTs will require more, not less, attention to informed consent, to ensure that the patients have an opportunity to choose according to their own values and preferences.
The above considerations are recognized in some form by various commentators, as factors that would "engage preferences or values that are meaningful to patients." 10 
| Impracticability condition
As Table 1 shows, the tension between a pragmatically designed RCT and the requirements of informed consent can be resolved by either modifying the informed consent process (if doing so is ethically acceptable) or by modifying or abandoning the RCT. One aspect of the Table 1 that needs further elaboration is the fact that there could be ethically acceptable solutions that involve both a modification of an RCT and some alteration of traditional informed consent. For example, theoretically, there could be an ethically acceptable alternative in which some verbal consent mechanism is used but which requires, on average, that a clinic schedule slightly fewer patients than usual during the period of protocol recruitment and to rewrite some additional software for the electronic health records so that the documentation of consent can be reliably verified. The cost of implementing these modification to the pragmatic trial may be acceptable, and from the ethical point of view, the verbal consent may be sufficient (upon analysis of a particular study).
Another issue that the impracticability criterion raises is that the condition essentially assumes a default: A waiver or alteration cannot be considered as an option unless the RCT is impracticable without waiver or alteration of the informed consent procedures. However, from an ethical point of view, it is possible that for some RCTs, this 
